T2 Biosystems, Inc. (TTOO)
NASDAQ: TTOO · IEX Real-Time Price · USD
2.840
+0.100 (3.65%)
At close: Apr 26, 2024, 4:00 PM
2.850
+0.010 (0.35%)
After-hours: Apr 26, 2024, 7:58 PM EDT
T2 Biosystems Revenue
In the year 2023, T2 Biosystems had annual revenue of $7.19M, a decrease of -67.75%. Revenue in the quarter ending December 31, 2023 was $1.68M, a -69.38% decrease year-over-year.
Revenue (ttm)
$7.19M
Revenue Growth
-67.75%
P/S Ratio
2.18
Revenue / Employee
$63,655
Employees
113
Market Cap
15.66M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7.19M | -15.11M | -67.75% |
Dec 31, 2022 | 22.31M | -5.75M | -20.50% |
Dec 31, 2021 | 28.06M | 9.93M | 54.76% |
Dec 31, 2020 | 18.13M | 9.80M | 117.52% |
Dec 31, 2019 | 8.34M | -2.17M | -20.62% |
Dec 31, 2018 | 10.50M | 5.83M | 125.03% |
Dec 31, 2017 | 4.67M | 586.00K | 14.36% |
Dec 31, 2016 | 4.08M | 1.27M | 45.04% |
Dec 31, 2015 | 2.81M | 2.69M | 2,263.87% |
Dec 31, 2014 | 119.00K | -147.00K | -55.26% |
Dec 31, 2013 | 266.00K | 247.00K | 1,300.00% |
Dec 31, 2012 | 19.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ETAO International Co. | 58.06M |
Psychemedics | 22.10M |
Immuron | 2.43M |
Avalo Therapeutics | 1.92M |
Mainz Biomed B.V. | 895.48K |
iBio, Inc. | 50.00K |
BioSig Technologies | 18.00K |
TTOO News
- 3 days ago - T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024 - GlobeNewsWire
- 16 days ago - T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity - GlobeNewsWire
- 4 weeks ago - T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc. - GlobeNewsWire
- 5 weeks ago - T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates - GlobeNewsWire
- 5 weeks ago - T2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business Updates - GlobeNewsWire
- 5 weeks ago - T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel - GlobeNewsWire
- 6 weeks ago - T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement - GlobeNewsWire
- 2 months ago - T2 Biosystems (TTOO) share price stays stable post Q4 earnings - Invezz